The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...

The going has been good for the German pharmaceutical giant Bayer BAYRY this year. Shares have surged 62.9% year to date ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.

US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...

Bayer's Kerendia has won FDA approval for a new heart failure indication thought to be pivotal for the product's blockbuster sales prospects.

Bayer is a deep contrarian play, trading at less than 6x P/E, with potential for 100%+ upside if litigation risks subside.

Bayer's Kerendia has won FDA approval for a new heart failure indication thought to be pivotal for the product's blockbuster sales prospects. Medical affairs is evolving.